Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Combo produces ‘best response rate’ after first relapse in kids with AML
Key clinical point: Administering CPX-351 prior to a three-drug regimen produced a high response rate in pediatric patients with acute myeloid leukemia in first relapse.
Major finding: CPX-351 followed by fludarabine, cytarabine, and filgrastim produced an overall response rate of 81%.
Study details: Phase 1/2 trial of 38 patients.
Disclosures: The trial was sponsored by the Children’s Oncology Group in collaboration with the National Cancer Institute. The speaker disclosed relationships with Juno Therapeutics and Celgene.
Citation:
Cooper TM et al. ASCO 2019. Abstract 10003.